Biological Features and Clinical Outcome by Age in 344 AML Patients
| . | <55 yr . | >55 yr . | P . |
|---|---|---|---|
| Favorable cytogenetics | 32/109 (29) | 15/116 (13) | .008 |
| Intermediate cytogenetics | 37/109 (34) | 43/116 (37) | .008 |
| Unfavorable cytogenetics | 40/109 (37) | 58/116 (50) | .008 |
| MDR1 | 56/113 (50) | 80/147 (54) | NS |
| CD34 | 83/136 (61) | 112/183 (61) | NS |
| CR | 89/134 (66) | 69/179 (40) | <.001 |
| . | <55 yr . | >55 yr . | P . |
|---|---|---|---|
| Favorable cytogenetics | 32/109 (29) | 15/116 (13) | .008 |
| Intermediate cytogenetics | 37/109 (34) | 43/116 (37) | .008 |
| Unfavorable cytogenetics | 40/109 (37) | 58/116 (50) | .008 |
| MDR1 | 56/113 (50) | 80/147 (54) | NS |
| CD34 | 83/136 (61) | 112/183 (61) | NS |
| CR | 89/134 (66) | 69/179 (40) | <.001 |
Values are the number of positive cases/number of cases evaluated (percentages in parentheses).
Abbreviation: NS, not significant.